From the Case Western Reserve University School of Medicine, Health Education Campus.
Departments of Radiology.
J Comput Assist Tomogr. 2021;45(6):950-958. doi: 10.1097/RCT.0000000000001204.
Lung cancer continues to be a major cause of death throughout the world. The ability to both accurately diagnose lung cancer in its early stages and monitor response to treatment is essential to reducing the morbidity and mortality associated with the disease. Serum tumor markers have been identified as potential biomarkers that may aid in lung cancer diagnosis and surveillance. These markers, when combined with cross-sectional imaging, may result in more robust screening and surveillance protocols. The future role of serum tumor markers in lung cancer includes the advancement of "liquid biopsies," in which peripheral blood samples are analyzed for tumor components without the need for a tissue biopsy.
肺癌仍然是全世界主要的死亡原因之一。能够准确诊断肺癌早期并监测治疗反应对于降低与该疾病相关的发病率和死亡率至关重要。血清肿瘤标志物已被确定为可能有助于肺癌诊断和监测的潜在生物标志物。这些标志物与横断面成像相结合,可能会产生更强大的筛查和监测方案。血清肿瘤标志物在肺癌中的未来作用包括“液体活检”的发展,即无需组织活检即可分析外周血样中的肿瘤成分。